DongKoo Bio & Pharma Co., Ltd. (KOSDAQ:006620)

Market Cap	151.44B
Revenue (ttm)	249.27B
Net Income (ttm)	2.04B
Shares Out	27.04M
EPS (ttm)	74.54
PE Ratio	75.13
Forward PE	n/a
Dividend	120.00 (2.22%)
Ex-Dividend Date	Dec 27, 2024

Volume	204,895
Average Volume	86,641
Open	5,430.00
Previous Close	5,410.00
Day's Range	5,420.00 - 5,790.00
52-Week Range	4,300.00 - 8,990.00
Beta	0.81
RSI	59.19
Earnings Date	May 14, 2025

About DongKoo Bio & Pharma

DongKoo Bio & Pharma Co., Ltd. manufactures and sells pharmaceuticals in South Korea. The company provides prescription drugs, such as antihistamines, dermatological oral medications, ophthalmic solutions, skeletal muscle relaxants, anti-inflammatory enzymes, antivirals, antibacterial agents, and for the treatment of allergies, liver diseases, mental illnesses, obesity, brain nervous, and endocrine systems; over-the-counter medicines, such as dermatological external preparations, antifungal agents, active probiotic intestinal supplements, antip...

• Industry: Pharmaceutical Preparations
• Founded: 1970
• Employees: 381
• Stock Exchange: KOSDAQ
• Ticker Symbol: 006620

Financial Performance

In 2024, DongKoo Bio & Pharma's revenue was 249.27 billion, an increase of 15.57% compared to the previous year's 215.69 billion. Earnings were 2.04 billion, a decrease of -82.77%.